Effect of Intravenous Dexmedetomidine Versus Dexamethasone for Management of Repound Pain After Supraclavicular Brachial Plexus Block

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06304909

Enrollment

111

Registered

2024-03-12

Start date

2024-05-15

Completion date

2025-03-20

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trauma Injury

Brief summary

Effect of intravenous dexmedetomidine versus dexamethasone for management of repound pain after supraclavicular brachial plexus block.

Interventions

DRUGDexmedetomidine injection

Dexmedetomidine group will receive 0.5 mcg/kg

DRUGDexamethasone

Dexamethasone group will receive 8mg/kg

DRUGSaline

receive equivalent volume of saline 0.9%.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients between 20\_60 years old * Patients with ASA clinical status I/II * Patients scheduled for peripheral nerve block for upper extremity surgery

Exclusion criteria

* 1\) they refused to participate 2) had preexisting neuropathy of the surgical limb 3) hypersensitivity to amide anesthetic 4) significant pulmonary disease 5) coagulopathy 6) sepsis 7) infection at the block site 8) hypersensitivity to dexmedetomidine \& dexamethasone

Design outcomes

Primary

Measure	Time frame	Description
The incidence of rebound pain.	1year	Rebound pain is defined as an increase from well-controlled to severe pain typically within 12\_24 h of resolution of the nerve block.

Countries

Egypt

Contacts

STUDY_DIRECTORWesam Nashat Ali, professor

Assistant professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026